CD24 and plasma cell myeloma: Our results are consistent with previous studies demonstrating the role of CD24 in recurrent follicular lymphoma [24], in R-CHOP treatment response and tumor immunosuppression in diffuse large B-cell lymphoma [25] and in multiple myeloma tumorigenicity [26].